Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. The JSPR news feed highlights company announcements on clinical data, corporate developments and financing activities that shape the outlook for this mast cell–focused program.
News updates commonly cover clinical trial results and study updates. Jasper has reported data from the BEACON Phase 1b/2a study in CSU, an open-label extension study in chronic urticarias, and the ETESIAN Phase 1b/2a study in allergic asthma. These releases describe endpoints such as Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils, serum tryptase, and safety findings, including observations related to KIT blockade.
The JSPR news stream also includes corporate and strategic announcements, such as leadership changes, corporate reorganizations, and decisions to concentrate resources on briquilimab in mast cell driven diseases. Investors can find information on Jasper’s participation in healthcare and investor conferences, where management discusses briquilimab’s development and provides program updates.
In addition, Jasper issues financing and capital markets news, including details of public offerings of common stock, pre-funded warrants and common warrants, and stated uses of proceeds for advancing briquilimab and supporting general corporate purposes. Together, these news items provide context on clinical progress, strategic focus and funding for Jasper’s lead program. For readers tracking JSPR, this page offers a centralized view of the company’s press releases and related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology firm focused on briquilimab, announced the appointment of Matthew Ford as Vice President of Human Resources. Ford, who has extensive experience in the pharma industry, previously held a senior HR role at Tricida and has worked with Jazz Pharmaceuticals and Gilead Sciences. His appointment aims to strengthen the company’s leadership and support the ongoing development of briquilimab, which targets diseases like chronic spontaneous urticaria and myelodysplastic syndromes. Jasper's briquilimab is in clinical trials, demonstrating safety and efficacy in over 130 subjects related to various conditions, including sickle cell disease and severe combined immunodeficiency.
Jasper Therapeutics (Nasdaq: JSPR) announced the appointment of David Hinds as Senior Vice President of Development Operations on April 10, 2023. Hinds, who has over 25 years of experience in clinical program development, is expected to play a crucial role in advancing briquilimab, an antibody therapy targeting c-Kit (CD117). This therapy aims to treat chronic spontaneous urticaria and lower-risk myelodysplastic syndromes (MDS) while enhancing stem cell transplant conditioning. CEO Ronald Martell expressed confidence in Hinds' ability to lead the clinical development phase effectively, including studies for chronic spontaneous urticaria and MDS. Jasper has demonstrated briquilimab's safety and efficacy in over 130 subjects and aims to further its development in various therapeutic areas.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the Cantor Fitzgerald The Future of Oncology Virtual Symposium from April 3-5, 2023. Senior Vice President Wendy Pang will join a panel discussion on April 5 at 1:00 PM ET, addressing novel mechanisms for hematological malignancies. Jasper is developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS). The therapy has shown promising safety and efficacy in over 130 subjects, with implications for stem cell transplants in rare diseases.
Jasper Therapeutics (Nasdaq: JSPR) has appointed Daniel Adelman, M.D., as its Acting Chief Medical Officer. Adelman brings over 30 years of experience in clinical development, particularly for immunologic diseases, holding leadership roles at companies such as Aimmune and Genentech. CEO Ron Martell expressed enthusiasm about Adelman's addition, citing his expertise as crucial for advancing their novel antibody therapy, briquilimab. This drug targets c-Kit for conditions like chronic spontaneous urticaria and myelodysplastic syndromes. Briquilimab has shown promising efficacy and safety in over 130 subjects, positioning Jasper for potential market success.